Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective December 1, 2023, the Compensation Committee of Blueprint Medicines'...
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP...
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective November 1, 2023, the Compensation Committee of Blueprint Medicines'...
Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the third quarter ended September...
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday,...
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective October 1, 2023, the Compensation Committee of Blueprint Medicines'...
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective September 1, 2023, the Compensation Committee of Blueprint Medicines' ...
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective August 1, 2023, the Compensation Committee of Blueprint Medicines'...
Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30,...
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday,...
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective July 1, 2023, the Compensation Committee of Blueprint Medicines'...
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective June 1, 2023, the Compensation Committee of Blueprint Medicines'...
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 ...
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that NEJM Evidence, a journal from The New England Journal of Medicine Group, has...
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT® (avapritinib)...
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that, effective May 1, 2023, the Compensation Committee of Blueprint Medicines' Board...
Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31,...
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision...
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May...
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced its participation in the following upcoming investor conferences: 22nd Annual Needham...
Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on ...
-- AYVAKIT achieved a statistically significant and clinically meaningful improvement in total symptom score that deepened over time, with...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.